Alantra advises SK Capital Partners on the sale of Florachem to Tradebe Life Sciences

Apr 2025

Sell-side advisory

New York – Alantra has acted as exclusive financial advisor to SK Capital Partners, LP (“SK Capital”), a private investment firm focused on the specialty materials, ingredients, and life sciences sectors, on the sale of Florachem Corporation (“Florachem” or the “Company”) to Tradebe, a Barcelona-based global business group dedicated to sustainability.

Florachem will join Tradebe’s Life Sciences business line, which is focused on creating a circular economy by purifying and manufacturing essential ingredients. This strategic combination in the flavor and fragrance (F&F) ingredients industry brings together complementary, naturally derived product portfolios to offer fulsome F&F solutions. It also represents Tradebe Life Sciences’ entry into the North American market and allows Florachem to further expand its international reach.

Headquartered in Jacksonville, FL, Florachem is a leading provider of naturally derived, high-value concentrated fractions, extracts, and natural ingredients. Since SK Capital’s acquisition of Florachem in April 2022, the Company has experienced significant growth driven by investments in the leadership team, organizational expansion, and the construction of a state-of-the-art, food-grade manufacturing facility in Lakeland, FL.

Michael Poerschke, Partner at Alantra, said: “This transaction showcases Florachem’s unique position in the F&F value chain and its evolution into a provider of high-value natural ingredients, and marks an important step in securing the right strategic partner for the next phase of its growth. By emphasizing Florachem’s scarcity value and differentiated capabilities in a highly competitive process, we were able to generate strong global interest and deliver a very successful outcome despite elevated broader market volatility.”

This transaction underscores Alantra’s momentum in the Ingredients sub-sector, in which the firm recently advised on a variety of transactions, including the sale of Pharm-Rx to New Mountain Capital and Actylis, MidOcean Partners and QualiTech on the acquisition of Ellison Bakery, and the shareholders of UST LLC on its sale to Somafina.